CY1109596T1 - Αναστολεις φωσφατασων cdc25 - Google Patents

Αναστολεις φωσφατασων cdc25

Info

Publication number
CY1109596T1
CY1109596T1 CY20091101174T CY091101174T CY1109596T1 CY 1109596 T1 CY1109596 T1 CY 1109596T1 CY 20091101174 T CY20091101174 T CY 20091101174T CY 091101174 T CY091101174 T CY 091101174T CY 1109596 T1 CY1109596 T1 CY 1109596T1
Authority
CY
Cyprus
Prior art keywords
cdc25
phosphate inhibitors
dione
inhibitors
phosphate
Prior art date
Application number
CY20091101174T
Other languages
English (en)
Inventor
Alban Sidhu
Grégoire Prevost
Dennis Bigg
Contour Marie-Odile Galcera
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Publication of CY1109596T1 publication Critical patent/CY1109596T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Η παρούσα εφεύρεση έχει ως αντικείμενο νέες ενώσεις, οι οποίες περιλαμβάνουν 2 ή 3 δομικούς λίθους του τύπου βενζοθειαζολο-4,7-διονών ή βενζοοξαζολο-4,7-διονών, οι οποίοι αναστέλλουν τις φωσφατάσες cdc25, και ειδικότερα τη φωσφατάση cdc25-C. Οι ενώσεις αυτές ημπορούν κυρίως να χρησιμοποιηθούν εις την θεραπευτική αγωγή του καρκίνου.
CY20091101174T 2004-12-17 2009-11-11 Αναστολεις φωσφατασων cdc25 CY1109596T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413456A FR2879598B1 (fr) 2004-12-17 2004-12-17 Inhibiteurs de phosphatases cdc25
EP05826562A EP1831209B1 (fr) 2004-12-17 2005-12-16 Inhibiteurs de phosphatases cdc25

Publications (1)

Publication Number Publication Date
CY1109596T1 true CY1109596T1 (el) 2014-08-13

Family

ID=34954106

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101174T CY1109596T1 (el) 2004-12-17 2009-11-11 Αναστολεις φωσφατασων cdc25

Country Status (15)

Country Link
US (1) US8017637B2 (el)
EP (1) EP1831209B1 (el)
JP (1) JP2008524175A (el)
AT (1) ATE439359T1 (el)
CA (1) CA2591215A1 (el)
CY (1) CY1109596T1 (el)
DE (1) DE602005016014D1 (el)
DK (1) DK1831209T3 (el)
ES (1) ES2331199T3 (el)
FR (1) FR2879598B1 (el)
PL (1) PL1831209T3 (el)
PT (1) PT1831209E (el)
RU (1) RU2395510C2 (el)
SI (1) SI1831209T1 (el)
WO (1) WO2006067311A2 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2877667B1 (fr) * 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2915747B1 (fr) * 2007-05-04 2011-02-25 Scras Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
SG10201707409PA (en) 2013-03-13 2017-10-30 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
WO2016046414A2 (en) 2014-09-26 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1534275A (en) 1976-01-30 1978-11-29 Shell Int Research Herbicidal compositions containing 1,4-quinones or derivatives thereof
US5508289A (en) * 1994-03-14 1996-04-16 The United States America As Represented By The Department Of Health And Human Services Bis-acridone chemotherapeutic derivatives
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
IT1293525B1 (it) * 1997-08-01 1999-03-01 Uni Degli Studi Camerino Bis-acridincarbossiammidi aventi attivita' antitumorale
EP1233787B8 (fr) 1999-11-09 2005-05-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Produit comprenant un inhibiteur de la transduction des signaux des proteines g heterotrimeriques en association avec un autre agent anti-cancereux pour une utilisation therapeutique dans le traitement du cancer
JP2003518039A (ja) 1999-12-21 2003-06-03 アストラゼネカ アクチボラグ Ｃｄ４５阻害剤
TW200304375A (en) 2001-12-06 2003-10-01 Maxia Pharmaceuticals Inc 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer
ATE368654T1 (de) * 2001-12-27 2007-08-15 Sod Conseils Rech Applic Benzothiazol- und benzoxazol-4,7-dionderivate und ihre verwendung als cdc25-phosphatasen- inhibitoren
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25

Also Published As

Publication number Publication date
US20090275624A1 (en) 2009-11-05
ATE439359T1 (de) 2009-08-15
DK1831209T3 (da) 2009-11-30
WO2006067311A3 (fr) 2006-08-17
SI1831209T1 (sl) 2010-01-29
RU2395510C2 (ru) 2010-07-27
RU2007127250A (ru) 2009-01-27
FR2879598A1 (fr) 2006-06-23
CA2591215A1 (fr) 2006-06-29
US8017637B2 (en) 2011-09-13
ES2331199T3 (es) 2009-12-23
PL1831209T3 (pl) 2010-01-29
EP1831209A2 (fr) 2007-09-12
JP2008524175A (ja) 2008-07-10
EP1831209B1 (fr) 2009-08-12
FR2879598B1 (fr) 2007-03-30
WO2006067311A2 (fr) 2006-06-29
DE602005016014D1 (de) 2009-09-24
PT1831209E (pt) 2009-11-04

Similar Documents

Publication Publication Date Title
CY1109596T1 (el) Αναστολεις φωσφατασων cdc25
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
NO20081636L (no) FAP - inhibitorer
BR0313330A (pt) Piperidina-ftalazonas substituìdas com pirrolidinadiona como inibidores de pde4
GEP20125368B (en) Kinase inhibitors
MD20150085A2 (ro) Inhibitori ai histon-demetilazelor
BRPI0606379A2 (pt) triazolftalazinas
ATE471324T1 (de) Triazolophthalazine
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
TWI367886B (en) Proteasome inhibitors and methods of using the same
MY146037A (en) Isoquinoline derivatives as inhibitors of rho-kinase
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
MX2008001053A (es) Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa.
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA201170344A1 (ru) Азаиндольные ингибиторы iap
MA31435B1 (fr) Inhibition de metastases tumorales par des anticoprs anti-neuropiline 2
MX2010007543A (es) Inhibidores de iap.
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
DK1814879T3 (da) Derivater af 4,7-dioxobenzothiazol-2-caboxamider, fremgangsmåde til fremstilling deraf og terapeutiske anvendelser af samme
DE60329326D1 (de) Tace inhibitoren
EA200701815A1 (ru) 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний